Within the generalized context of containing public pharmaceutical spending in Spain, price and financing negotiations for new medicines constitute a vital process for the sustainability of the Sistema Nacional de Salud. It is in this aspect, where pharmacoeconomic studies play a relevant role, being a key tool for decision-making and for improving efficiency levels in the National Health System.

From our Pharmacoeconomics department, we facilitate these negotiations by creating or adapting different economic evaluation studies: cost-benefit analysis, cost-effectiveness analysis, cost-utility analysis and cost minimization analysis using, if necessary, the needed techniques of modeling (decision trees or Markov models). We also provide the necessary arguments through drafts of therapeutic positioning reports, product value dossiers and budgetary impacts.